Key Highlights
- Zoetis shares ticked down 0.95% to $80.02, against a prior close of $80.79.
- The stock fell 5.59% on Thursday.
- Livestock sales grew 7% last quarter, while pet sales fell 5%.
- Barclays holds a Hold rating with an $85 target.
- The next catalyst is the fourth-quarter report in February.
Product Milestones Meet Companion-Animal Softness
Zoetis (NYSE:ZTS) shares ticked down 0.95% to $80.02 on Friday, on Volume of about 2.74 million shares. Investors weighed a string of product milestones, including a USDA license for the Poulvac Procerta HVT-ND-ILT chicken Vaccine and the Cytopoint Plus approval, against softness in the companion-animal business.
The stock fell 5.59% on Thursday, when it underperformed peers, and a broad AI-driven selloff continues to weigh on the market.
Livestock Growth Offsets a Pet Sales Decline
Livestock sales grew 7% last quarter, while pet sales fell 5%. Analysts see the approvals as incremental, as the near-term story depends on stabilizing US companion-animal demand.
The consensus rating is Hold, and Barclays holds a Hold rating with an $85 target.
Valuation and Animal Health Peers Mixed
Zoetis trades at about 12.95 times forward Earnings and 13.60 times trailing earnings, on Earnings Per Share of $6.58. The Dividend Yield is 2.65%, and the 52-week range runs from $68.77 to $132.49.
Peers were mixed. Merck (NYSE:MRK) rose 1.40%, while Elanco (NYSE:ELAN) fell 2.11%, IDEXX Laboratories (NASDAQ:IDXX) dropped 0.92% and Phibro Animal Health (NASDAQ:PAHC) slipped 1.97%.
Companion-Animal Stabilization and the February Report Are the Markers
Zoetis trades far below its 52-week high on Demand worries. Investors will watch for companion-animal stabilization and the fourth-quarter report in February.






Please wait processing your request...